Company: TELO
Filing Date: 2025-06-11
Form Type: 8-K
Source: 0001641172-25-014648
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Function in Wilson’s
Disease Animal Model

On
June 11, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced new preclinical data demonstrating that its lead small molecule
candidate, Telomir-1, significantly improved neurological, behavioral, liver- and kidney-related outcomes in a clinically relevant animal
model of Wilson’s disease (ATP7B C271X -/- zebrafish).

Wilson’s
disease is a rare and potentially life-threatening genetic disorder caused by mutations in the ATP7B gene, which impair the body’s
ability to eliminate excess copper.

In
this preclinical study, Telomir-1 demonstrated dose-dependent and statistically significant reversal of multiple disease-relevant endpoints
in the Wilson’s disease model:

  Up                                                                                                                                     
  Normalization                                                                                                                          
  Reversal                                                                                                                               
  Approximately                                                                                                                          
  Significant                                                                                                                            
  Normalization                                                                                                                          
  Improved                                                                                                                               

The
study demonstrated that Telomir-1 produced a statistically significant and dose-dependent reversal of neurological dysfunction, liver
and kidney damage, copper accumulation, and mortality in a clinically relevant genetic model of Wilson’s disease.

Telomir
Pharmaceuticals is operating at full speed and currently advancing Telomir-1 toward an IND submission in a rare disease indication by
year-end, with human clinical trials planned for the first half of 2026.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     TELOMIR                                       
  Dated:             By:                        /s/                
                     Name:                      Erez               
                     Title:                     Chief